RESUMO
Social housing has often been recommended as one-way to address the psychological well-being of captive non-human primates. Published reports have examined methods to socialize compatible animals by forming pairs or groups. Successful socialization rates vary depending on the species, gender, and environment. This study presents a retrospective look at pairing attempts in two species of owl monkeys, Aotus nancymaae and A. azarae, which live in monogamous pairs in the wild. The results of 477 pairing attempt conducted with captive, laboratory housed owl monkeys and 61 hr of behavioral observations are reported here. The greatest success pairing these owl monkeys occurred with opposite sex pairs, with an 82% success rate. Opposite sex pairs were more successful when females were older than males. Female-female pairs were more successful than male-male (MM) pairs (62% vs 40%). Successful pairs stayed together between 3 and 7 years before the animals were separated due to social incompatibility. Vigilance, eating, and sleeping during introductions significantly predicted success, as did the performance of the same behavior in both animals. The results of this analysis show that it is possible to give captive owl monkeys a social alternative even if species appropriate social partners (i.e., opposite sex partners) are not available. The focus of this report is a description of one potential way to enhance the welfare of a specific new world primate, the owl monkey, under laboratory conditions. More important is how the species typical social structure of owl monkeys in nature affects the captive management of this genus. Am. J. Primatol. 79:e22521, 2017. © 2015 Wiley Periodicals, Inc.
Assuntos
Aotidae , Ligação do Par , Socialização , Animais , Cebidae , Feminino , Masculino , Estudos Retrospectivos , Comportamento SocialRESUMO
Anemia has long been reported to adversely affect the efficacy of radiation treatment in cervical cancer. On the basis of these findings, many radiation oncologists routinely use blood transfusions with the intent to maintain hemoglobin above specified levels during radiation therapy. However, allogeneic blood transfusions have been previously linked with biological and clinical phenomena correlated with immune suppression. In this study we have analyzed the effects of blood transfusion on the outcome of 130 patients with stage-IIB and -III cervical carcinomas treated with external radiation and intracavitary brachytherapy with or without concomitant platinum administration at the University of Arkansas for Medical Sciences between 1990 and 1999. With the exception of hemoglobin and hematocrit levels at the onset of treatment between the transfused and untransfused groups (p < 0.001), the distribution of age, histology, total radiation dose and duration of treatment were not significantly different between the 2 groups of stage-IIB and -III patients. Among the 45 stage-IIB patients who received blood during radiation treatment, there were 31 deaths (68.8%), compared with 14 (31.8%) among the 44 patients who did not receive blood (p > 0.05). Among the 30 stage-III patients who received blood during radiation treatment, there were 27 deaths (90%), compared with 6 (54%) among the 11 patients who did not receive blood (p > 0.11). In multivariate analysis of survival, there was a significant difference due to transfusion with a risk ratio (RR) of 2.6 (95% CI 1.6, 4.2; p < 0.001) after adjusting for no chemotherapy (RR = 2.2, 95% CI 1.4, 3.5; p < 0.001), considering all patients collectively, stage-IIB patients only (RR = 1.9, 95% CI 1.1, 3.3; p < 0.01), and stage-III patients only (RR = 3.2, 95% CI 1.2, 8.7; p < 0.02). These results suggest that routine blood transfusion of anemic cervical cancer patients does not improve outcome and may represent an independent variable predictive of diminished survival during primary radiation treatment for cervical cancer. Prospective randomized studies are strongly warranted to confirm this hypothesis.
Assuntos
Transfusão de Sangue , Resultado do Tratamento , Neoplasias do Colo do Útero/radioterapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Hematócrito , Hemoglobinas/análise , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/epidemiologia , Estadiamento de Neoplasias , Transplante Homólogo , Neoplasias do Colo do Útero/mortalidade , Neoplasias do Colo do Útero/patologiaRESUMO
We describe a 65-year-old woman with a large surgically unresectable and chemoresistant liver metastasis of endometrial carcinoma who was treated by infusion with peripheral blood T cells stimulated with tumor lysate-pulsed autologous dendritic cells (DC). Extensive in vitro characterization of the DC-activated T cells included phenotypic analysis, cytotoxicity, and intracellular cytokine secretion. High cytotoxicity was observed against autologous tumor cells, but not against NK-sensitive K562 cells, autologous Con-A lymphoblasts, or autologous Epstein-Barr virus-transformed lymphoblastoid cells. Blocking studies demonstrated that lytic activity was HLA class I restricted. Two-color flow cytometric analysis revealed that a significant proportion of CD8+ T cells was also CD56+, and analysis of intracellular IFN-gamma and IL-4 expression suggested a type 1 cytokine bias. The patient was treated by three infusions of tumor-specific T cells at 3- to 4-week intervals, and in vivo distribution of the T cells was followed by (111)In oxine labeling and serial gamma camera imaging. Tumor localization and accumulation of labeled lymphocytes was consistently detected at serial time points following each injection. However, deep infiltration of the large tumor mass by activated T cells was minimal, as evaluated in 3 dimensions by single photon emission computerized tomography (SPECT) imaging. Transient serum increases of the tumor marker lactate dehydrogenase (LDH), were detectable after each injection. Similar posttreatment elevations were seen for serum uric acid and potassium. Clinically, stabilization of the large liver metastasis was obtained during treatment. Collectively, these results indicate that tumor-specific CD8+ cytotoxic T-cell responses can be generated in patients with endometrial cancer, and suggest that T-cell immunotherapy may be of therapeutic value in patients harboring metastatic disease.
Assuntos
Células Dendríticas/imunologia , Neoplasias do Endométrio/terapia , Imunoterapia Adotiva , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Linfócitos T/imunologia , Idoso , Antígeno CD56/análise , Linfócitos T CD8-Positivos/imunologia , Terapia Combinada , Feminino , Citometria de Fluxo , Artéria Hepática , Antígenos de Histocompatibilidade Classe I/análise , Humanos , Imunofenotipagem , L-Lactato Desidrogenase/sangue , Neoplasias Hepáticas/radioterapia , Tomografia Computadorizada por Raios X , Ácido Úrico/sangueRESUMO
Limited data are available concerning the outcome of patients with atypical and malignant meningiomas. We therefore analyzed the outcome of seventeen patients with meningiomas (9 atypical; 8 malignant) at Thomas Jefferson University Hospital between 1973 and 1996. Strict adherence to the 1993 WHO criteria for the typing of CNS tumors was maintained. The median potential follow-up period for all patients was 87 months. The age at diagnosis ranged from 22 to 72 (mean 51.8 years). There were 5 males and 12 females. The mean tumor diameter was 4.45 cm. Of the 16 cases where the extent of surgical resection was known, 4 were partial and 12 were complete resections. Six patients (35%) had dural or cortical invasion by tumor. Fifteen patients received postoperative megavoltage photon irradiation (mean 61 Gy). One of these fifteen pts. received an additional 20 Gy with Au-198 implantation and 1 received post-radiation chemotherapy for recurrent disease. The overall survival rate for all patients at 5 and 10 years were 87% and 58% respectively. The 5- and 10-year survival rates for atypical meningiomas were 87% and 58%; for malignant meningiomas the survival rates were 60% and 60% respectively. Five patients (30%) have died. Three of these 5 patients initially received less than 54 Gy to the tumor bed and have died of recurrent disease. Local disease progression was documented in 11 patients (65%) after surgery and in 3 patients (18%) after radiation. There was an improvement in performance status in 3 (18%) patients with a decline and no change seen in 1 (6%) and 13 (77%) respectively after receiving radiation. There appeared to be no difference in survival in patients as a function of dural or cortical invasion. Long term survival is possible for patients with atypical and malignant meningiomas treated with surgery and post-operative radiation. We are unable to distinguish a difference in outcome between these two pathological entities. Dural and cortical invasion were not associated with a decrease in survival. In addition, improved tumor control and survival may be associated with increased radiation dose.
Assuntos
Neoplasias Meníngeas/patologia , Meningioma/patologia , Adulto , Idoso , Braquiterapia , Feminino , Seguimentos , Radioisótopos de Ouro/uso terapêutico , Humanos , Avaliação de Estado de Karnofsky , Masculino , Neoplasias Meníngeas/mortalidade , Neoplasias Meníngeas/radioterapia , Neoplasias Meníngeas/cirurgia , Meningioma/mortalidade , Meningioma/radioterapia , Meningioma/cirurgia , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Radioterapia de Alta Energia , Análise de Sobrevida , Resultado do TratamentoRESUMO
OBJECTIVE: We describe our initial experience with fractionated stereotactic radiotherapy (SRT) for the treatment of 19 patients with secretory and nonsecretory pituitary macroadenomas. The primary endpoints of local control and the documentation of any MRI T2-weighted changes in contiguous brain tissues are discussed. METHODS: Between 1/95 and 1/97, 19 patients were planned with the X-Knife 3-D planning system (Radionics, Burlington, Mass., USA) and received a median dose of 46 Gy in daily 2.0-Gy fractions. Treatments were delivered stereotactically with a dedicated 600SR linear accelerator (Varian Corporation, Palo Alto, Calif., USA). Immobilization was achieved with the Gill-Thomas-Cosman relocatable frame. The mean tumor size was 2.24 cm. The mean prescription isodose was 87%. The mean age was 53 years (10 male, 9 female). The mean follow-up time was 10 months (range 1-24 months). The mean optic chiasm and brain stem doses were calculated at 38 and 13 Gy, respectively. All patients were evaluated with pre- and postgadolinum-enhanced MRI scans and Humphrey visual field tests. RESULTS: In the posttreatment period, local control (absence of tumor progression) has been achieved in all of the patients. The treatment was well tolerated in all patients. No acute complications, no visual changes and no T2-weighted MRI or proton density changes were documented in any of the 19 patients. CONCLUSION: These preliminary results suggest that SRT compares favorably with conventional radiotherapy in achieving local control. The doses to the brainstem and the temporal lobes are significantly decreased and at early follow-up no white matter changes are seen on MRI after SRT. The true frequency of grade 1-4 changes are likely underestimated as similar changes often occur in association with tumor edema or after surgery. Given the uncertain neurocognitive significance of the white matter changes associated with treating these benign tumors by conventional radiotherapy, we are currently treating all pituitary adenomas with fractionated SRT to reduce the potential sequelae.